Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
暂无分享,去创建一个
E. Cook | M. Pencina | W. Manning | C. Autore | B. Maron | C. Rapezzi | M. Lombardi | M. Maron | R. Chan | I. Olivotto | F. Cecchi | H. Rakowski | C. Gibson | C. D. De Cecco | E. Rowin | C. Gibson | J. Udelson | A. Crean | S. Hong | J. Lesser | E. Cook | C. Gruner | E. Appelbaum | E. Biagini | P. Spirito | Tammy S. Haas | B. Tomberli | F. Formisano | G. Assenza | Francesco Formisano | Raymond H Chan
[1] Giuseppe Limongelli,et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.
[2] M. Maron. Contrast-enhanced CMR in HCM: what lies behind the bright light of LGE and why it now matters. , 2013, JACC. Cardiovascular imaging.
[3] Harry Rakowski,et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. , 2013, JACC. Cardiovascular imaging.
[4] B. Maron,et al. Hypertrophic cardiomyopathy – Authors' reply , 2013, The Lancet.
[5] M. Link,et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.
[6] R. Fattori,et al. Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis , 2012, BMJ Open.
[7] M. Pencina,et al. Interpreting incremental value of markers added to risk prediction models. , 2012, American journal of epidemiology.
[8] C. Kramer,et al. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. , 2012, JACC. Cardiovascular imaging.
[9] M. Maron,et al. Clinical Utility of Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy , 2012, Journal of Cardiovascular Magnetic Resonance.
[10] Barry J Maron,et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.
[11] Barry J Maron,et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.
[12] Pierre Croisille,et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. , 2011, Journal of the American College of Cardiology.
[13] Vivek Muthurangu,et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. , 2011, JACC. Cardiovascular imaging.
[14] R. Kwong,et al. Measuring myocardial scar by CMR. , 2011, JACC. Cardiovascular imaging.
[15] P. Core. Hypertrophic cardiomyopathy:quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging , 2011 .
[16] M. Cheitlin,et al. Myocardial Scar Visualized by Cardiovascular Magnetic Resonance Imaging Predicts Major Adverse Events in Patients With Hypertrophic Cardiomyopathy , 2011 .
[17] C. Kramer,et al. Prognosis in hypertrophic cardiomyopathy with contrast-enhanced cardiac magnetic resonance: the future looks bright. , 2010, Journal of the American College of Cardiology.
[18] W. Manning,et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.
[19] Lidia Chojnowska,et al. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. , 2010, European journal of radiology.
[20] Stefan O Schoenberg,et al. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[21] V. Positano,et al. Usefulness of delayed enhancement by magnetic resonance imaging in hypertrophic cardiomyopathy as a marker of disease and its severity. , 2010, The American journal of cardiology.
[22] B. Maron. Contemporary Reviews in Cardiovascular Medicine Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy , 2010 .
[23] M. Sheppard,et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance , 2010 .
[24] A. Tajik,et al. Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.
[25] D. Pennell,et al. Cardiovascular Magnetic Resonance , 2019, Cardiac CT, PET & MR.
[26] N. Smedira,et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. , 2009, Journal of the American College of Cardiology.
[27] W. Manning,et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. , 2009, Journal of the American College of Cardiology.
[28] R. Bonamini,et al. Extensive myocardial fibrosis in a patient with hypertrophic cardiomyopathy and ventricular tachycardia without traditional high-risk features. , 2009, Circulation Cardiovascular Imaging.
[29] J. Moon,et al. The emerging role of cardiovascular magnetic resonance in refining the diagnosis of hypertrophic cardiomyopathy , 2009, Nature Clinical Practice Cardiovascular Medicine.
[30] S. Prasad,et al. Cardiovascular magnetic resonance of cardiomyopathies , 2009, Current cardiology reports.
[31] M. Josephson,et al. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. , 2008, Journal of the American College of Cardiology.
[32] Warren J Manning,et al. Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy , 2008, Circulation. Heart failure.
[33] W. Roberts,et al. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. , 2008, The American journal of cardiology.
[34] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[35] Mario J. Garcia,et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study , 2008, The International Journal of Cardiovascular Imaging.
[36] M. Link,et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.
[37] W. Manning,et al. Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.
[38] C. Rochitte,et al. The emerging role of MRI in the diagnosis and management of cardiomyopathies , 2006, Current cardiology reports.
[39] M. Borggrefe,et al. CMR scarring in a patient with hypertrophic cardiomyopathy correlates well with histological findings of fibrosis. , 2005, European heart journal.
[40] Robert G. Hauser,et al. Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator , 2005, Circulation.
[41] B. Maron,et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.
[42] Dudley J Pennell,et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.
[43] C. Semsarian,et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.
[44] Barry J Maron,et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.
[45] P. Elliott,et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.
[46] D. Pennell,et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.
[47] Raymond J Kim,et al. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death? , 2003, Journal of the American College of Cardiology.
[48] Heiko Mahrholdt,et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.
[49] B. Maron. Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.
[50] M. Cerqueira,et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.
[51] P. Elliott,et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.
[52] B. Maron,et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.
[53] G Thiene,et al. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.
[54] M. Link,et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.
[55] W. Roberts,et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. , 2000, Journal of the American College of Cardiology.
[56] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[57] M. Burch,et al. Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.
[58] D TEARE,et al. ASYMMETRICAL HYPERTROPHY OF THE HEART IN YOUNG ADULTS , 1958, British heart journal.